Prelude Therapeutics (PRLD) Expected to Announce Earnings on Thursday

Prelude Therapeutics (NASDAQ:PRLD) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Prelude Therapeutics Stock Performance

Shares of PRLD stock opened at $0.95 on Wednesday. Prelude Therapeutics has a one year low of $0.80 and a one year high of $6.80. The company has a 50 day moving average price of $1.10 and a 200 day moving average price of $2.16. The firm has a market capitalization of $52.21 million, a price-to-earnings ratio of -0.53 and a beta of 1.37.

Wall Street Analyst Weigh In

PRLD has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Insiders Place Their Bets

In other Prelude Therapeutics news, insider Andrew Combs acquired 60,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $1.37 per share, for a total transaction of $82,200.00. Following the completion of the purchase, the insider now directly owns 377,623 shares in the company, valued at $517,343.51. This represents a 18.89 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Krishna Vaddi acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were acquired at an average price of $0.93 per share, with a total value of $93,000.00. Following the completion of the purchase, the chief executive officer now owns 1,167,275 shares of the company’s stock, valued at $1,085,565.75. This trade represents a 9.37 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 198,075 shares of company stock worth $213,486 over the last ninety days. 62.80% of the stock is owned by company insiders.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.